S1.

Details of uncommon mutations and response to first-line EGFR-TKIs

Case	Sex	Age (year)	Smoking	Pathology	Status	Distant metastases	ECOG PS	TKI	Response	PFS (month)	EGFR mutation	Co-alteration
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status; PFS, progression-free survival; M, male; F, female; ADC, adenocarcinoma; SD, stable disease; PR, partial response; PD, progression disease.
1	M	51	Smoker	ADC	IV	No	1	Icotinib	SD	8.6	G719X	S768I
2	F	55	Never	ADC	IV	Yes	2	Gefitinib	SD	4.2	G719X	S768I
3	F	62	Never	ADC	Recurred	Yes	1	Gefitinib	SD	1.0+	G719X	S768I
4	M	67	Smoker	ADC	IV	No	1	Erlotinib	PR	7.1	G719X	L861Q
5	M	55	Smoker	ADC	IV	Yes	0	Icotinib	SD	2.2	G719X	L861Q
6	F	71	Never	ADC	IV	No	1	Gefitinib	SD	12.6	G719X
7	F	77	Never	ADC	NE	NE	1	Gefitinib	SD	12.1	G719X
8	M	74	Smoker	ADC	IV	No	1	Gefitinib	SD	9.6	G719X
9	F	70	Never	ADC	IV	No	1	Gefitinib	SD	8.5	G719X
10	M	62	Smoker	ADC	IV	Yes	1	Gefitinib	PR	8.2	G719X
11	M	63	Smoker	ADC	IV	No	1	Erlotinib	SD	4.9	G719X
12	M	62	Smoker	ADC	IV	Yes	2	Gefitinib	SD	3.8	G719X
13	M	68	Smoker	ADC	IV	No	1	Erlotinib	SD	3.0+	G719X
14	M	61	Smoker	ADC	IV	Yes	1	Gefitinib	SD	3.0	G719X
15	F	81	Never	ADC	IV	Yes	1	Gefitinib	PR	2.7+	G719X
16	M	62	Smoker	ADC	IV	Yes	1	Icotinib	PD	1.9	G719X
17	F	73	Never	ADC	IIIb	No	1	Gefitinib	SD	1.0+	G719X
18	F	58	Never	ADC	IV	Yes	1	Icotinib	SD	1.0+	G719X
19	F	22	Never	ADC	IV	No	1	Gefitinib	PR	4.4	S768I
20	M	72	Smoker	NOS	IV	Yes	1	Icotinib	PR	3.4	S768I
21	F	65	Never	ADC	IIIb	No	1	Gefitinib	SD	1.0+	S768I
22	M	54	Never	ADC	IV	Yes	1	Gefitinib	SD	9.8+	L861Q
23	F	49	Never	ADC	IV	Yes	1	Erlotinib	PR	8.9	L861Q
24	F	70	Never	ADC	Recurred	Yes	0	Gefitinib	SD	7.6	L861Q
25	F	55	Never	ADC	IV	Yes	1	Erlotinib	SD	4.1+	L861Q
26	M	45	Smoker	ADC	IV	Yes	0	Gefitinib	PR	3.7	L861Q
27	F	38	Never	ADC	IV	No	1	Gefitinib	SD	2.8	L861Q
28	M	69	Smoker	ADC	IV	No	1	Icotinib	SD	2.5+	L861Q
29	M	70	Never	ADC	IV	No	1	Erlotinib	PD	2.0	L861Q
30	M	79	Smoker	ADC	IV	No	1	Icotinib	SD	1.4+	L861Q